WO1992012992A3 - Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods - Google Patents

Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods Download PDF

Info

Publication number
WO1992012992A3
WO1992012992A3 PCT/US1992/000356 US9200356W WO9212992A3 WO 1992012992 A3 WO1992012992 A3 WO 1992012992A3 US 9200356 W US9200356 W US 9200356W WO 9212992 A3 WO9212992 A3 WO 9212992A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
polypeptides
hcv
immunogenic
fgb2
Prior art date
Application number
PCT/US1992/000356
Other languages
French (fr)
Other versions
WO1992012992A2 (en
Inventor
Girish J Kotwal
Bahige M Baroudy
Original Assignee
Gamble James N Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamble James N Med Inst filed Critical Gamble James N Med Inst
Publication of WO1992012992A2 publication Critical patent/WO1992012992A2/en
Publication of WO1992012992A3 publication Critical patent/WO1992012992A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel basic immunogenic polypeptides having epitopes for HCV are disclosed. The novel basic immunogenic polypeptides are truncated polypeptides derived from the structural region of a human HCV isolate. Two preferred novel basic immunogenic polypeptides are designated as FGB1 and FGB2. The FGB1 and FGB2 polypeptides are believed to be derived from near the N- and C-terminals, respectively, of a putative (C) protein of HCV. In an ELISA, eight serum samples reactive for anti-C100 HCV antibody (EIA, Ortho/Chiron), recombinant immunoblot assay I (RIBA I, Ortho/Chiron) and neutralization (Neut., Abbot Labs.) contained antibodies to the FGB1 and FGB2 polypeptides. In addition, the FGB1 and FGB2 polypeptides and RIBA I were non-reactive with twelve serum samples which were reactive with EIA. Still further, two serum samples from a patient clinically diagnosed as NANBH, which were non-reactive with EIA and RIBA I, were reactive with FGB1 and/or FGB2. Novel polynucleotide sequences encoding the basic immunogenic polypeptides are also disclosed. The present invention further includes the application of these new sequences, polypeptides, and antibodies raised against the novel polypeptides in HCV detection, such as immunoassays, diagnostics, PCR technology and gene therapy. Included within the invention also are novel immunogenic HCV polypeptides encoded within recombinant expression systems and clones, novel transformants, novel probes, novel methods for producing the immunogenic HCV polypeptides, novel anti-idiotype antibodies, novel antisense polynucleotides, and novel kits.
PCT/US1992/000356 1991-01-14 1992-01-14 Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods WO1992012992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63980991A 1991-01-14 1991-01-14
US639,809 1991-01-14

Publications (2)

Publication Number Publication Date
WO1992012992A2 WO1992012992A2 (en) 1992-08-06
WO1992012992A3 true WO1992012992A3 (en) 1993-03-18

Family

ID=24565635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/000356 WO1992012992A2 (en) 1991-01-14 1992-01-14 Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods

Country Status (3)

Country Link
EP (1) EP0571554A1 (en)
AU (1) AU1459792A (en)
WO (1) WO1992012992A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105871D0 (en) * 1991-03-20 1991-05-08 Inst Cientifico Tecnol Navarra Synthetic peptides
DE4209215A1 (en) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh HCV PEPTIDE ANTIGEN AND METHOD FOR DETERMINING HCV
CA2120340A1 (en) * 1991-10-02 1994-04-15 Kaichiro Ishibashi Reagents for testing for hepatitis c and method of testing for the same
DE4240980A1 (en) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV peptide antigens and method for the determination of HCV
JPH06311885A (en) * 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Anti-sense compound complementary with gene of hepatitis c virus
JPH08506479A (en) * 1992-09-10 1996-07-16 財団法人化学及血清療法研究所 Compositions and methods for the treatment of hepatitis C virus-related disorders
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
EP0759979A4 (en) * 1994-05-10 1999-10-20 Gen Hospital Corp Antisense inhibition of hepatitis c virus
AUPN283195A0 (en) * 1995-05-05 1995-06-01 Australian Water Technologies Pty Ltd Method for the detection of viable cryptosporidium parvum cells
AU707811B2 (en) * 1995-05-05 1999-07-22 Australian Water Technologies Pty Ltd Method for the detection of viable Cryptosporidium parvum oocysts
IT1285158B1 (en) * 1996-09-17 1998-06-03 Angeletti P Ist Richerche Bio SOLUBLE POLYPEPTIDES WITH THE SERINO-PROTEASIS ACTIVITY OF NS3 OF THE HEPATITIS C VIRUS, AND PROCEDURE FOR THEIR PREPARATION AND
DE19980730D2 (en) * 1998-04-28 2001-05-10 Wolfgang Bergter Radioimmunopharmaceuticals for the treatment of hepatitis C

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014436A1 (en) * 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
EP0442394A2 (en) * 1990-02-16 1991-08-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
EP0445423A2 (en) * 1989-12-22 1991-09-11 Abbott Laboratories Hepatitis C assay
EP0451891A2 (en) * 1990-03-30 1991-10-16 Akzo Nobel N.V. Peptides immunochemically reactive with antibodies directed against hepatitis Non-A, Non-B virus
EP0471356A1 (en) * 1990-08-14 1992-02-19 JAPAN as represented by Director General of Agency of NATIONAL INSTITUTE OF HEALTH Antigenic peptide for detecting anti-hepatitis C virus antibodies and use thereof
WO1992002642A1 (en) * 1990-08-10 1992-02-20 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
EP0479376A1 (en) * 1990-10-05 1992-04-08 Akzo Nobel N.V. Peptides immunochemically reactive with antibodies directed against hepatitis Non-A, Non-B virus
EP0485209A1 (en) * 1990-11-08 1992-05-13 Immuno Japan Inc. Non A, non B hepatitis virus related antigen, antibody detection systems, polynucleotides and polypeptides
EP0489968A1 (en) * 1990-12-14 1992-06-17 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014436A1 (en) * 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
EP0445423A2 (en) * 1989-12-22 1991-09-11 Abbott Laboratories Hepatitis C assay
EP0442394A2 (en) * 1990-02-16 1991-08-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
EP0451891A2 (en) * 1990-03-30 1991-10-16 Akzo Nobel N.V. Peptides immunochemically reactive with antibodies directed against hepatitis Non-A, Non-B virus
WO1992002642A1 (en) * 1990-08-10 1992-02-20 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
EP0471356A1 (en) * 1990-08-14 1992-02-19 JAPAN as represented by Director General of Agency of NATIONAL INSTITUTE OF HEALTH Antigenic peptide for detecting anti-hepatitis C virus antibodies and use thereof
EP0479376A1 (en) * 1990-10-05 1992-04-08 Akzo Nobel N.V. Peptides immunochemically reactive with antibodies directed against hepatitis Non-A, Non-B virus
EP0485209A1 (en) * 1990-11-08 1992-05-13 Immuno Japan Inc. Non A, non B hepatitis virus related antigen, antibody detection systems, polynucleotides and polypeptides
EP0489968A1 (en) * 1990-12-14 1992-06-17 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, vol. 172, no. 2, 30 October 1990, Academic Press, Inc., K. MURAISO et al.: "A structural protein of hepatitis C virus expressed in E. coli facilitates accurate detection of hepatitis C virus", pages 511-516, see the whole document *
Japan. J. Exp. Med., vol. 60, no. 3, June 1990, H. OKAMOTO et al.: "The 5'-terminal sequence of the hepatitis C virus genome", pages 167-177 *
Journal of General Virology, vol. 71, December 1990, (GB), K. TAKEUCHI et al.: "The putative nucleocapsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers", pages 3027-3033, see page 3032, column 2, last paragraph *
Proceedings of the 28th Symposium on Peptide Chemistry, Osaka, 25-27 October 1990, (ed. Y. SHIMONISHI), E. MUNEKATA et al.: "Epitope mapping of hepatitis C virus constituting protein", pages 211-214, see the whole document *

Also Published As

Publication number Publication date
AU1459792A (en) 1992-08-27
EP0571554A1 (en) 1993-12-01
WO1992012992A2 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
Bulinski et al. Peptide antibody specific for the amino terminus of skeletal muscle alpha-actin.
CA2005950C (en) Non-a, non-b hepatitis virus genome rna, cdna and virus antigen protein
UA50829C2 (en) Polynucleotide, vector, cells, expressing system, polypeptides, monoclonal antibodies, preparation of polyclonal antibodies, nucleotide probe, analytic kits, method for detecting nucleic acids, methods for immunoassay, vaccine, method for production of antibodies
US7670766B2 (en) Early detection of flaviviruses using the NS1 glycoprotein
WO1992012992A3 (en) Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
US6054264A (en) Methods of typing hepatitis C virus and reagents for use therein
JP2004512824A5 (en)
RU94024561A (en) IMMUNORACTIVE COMPOSITIONS, METHOD FOR PREPARING THE COMPOSITION, METHODS FOR OBTAINING AND DETECTING ANTIBODIES, DNA SET, HOST CELL, METHOD OF OBTAINING PROTEIN
JP2008515388A5 (en)
DK175843B1 (en) Polypeptides of Surfactant Alvelolar Proteins (ASP), Pharmaceutical Composition Containing the Polypeptide, DNA Expression System Encoding the Polypeptide, and Method of Preparing Polypeptides with ASP Activity
CA2098253C (en) Method for producing ectoprotein of hepatitis c virus
US5176994A (en) Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein
EP0516859A1 (en) Non-a non-b hepatitis virus antigen protein
CA2400007C (en) Immunization of an individual against carcinoma and the preliminary stages thereof
Handschuh et al. Bacterial expression and purification of hepatitis C virus capsid proteins of different size
JP2001522599A (en) Multimeric peptide derived from hepatitis C virus envelope protein for diagnosis and vaccine
KR100210200B1 (en) Recombinant microorganism which produce hcv e2 protein and preparing method of hcv e2 protein
EP0804473A1 (en) Methods and compositions for differential diagnosis of acute and chronic hepatitis c virus infection
CA2151128A1 (en) Hepatitis c virus (hcv) non-structural-3 peptides, antibodies thereto and methods for the detection of hcv
WO2001029079A1 (en) IMMUNO-INTERACTIVE FRAGMENTS OF THE αC SUBUNIT OF INHIBIN
EP0593291A2 (en) Nonstructural protein of hepatitis C virus, and diagnostic method and kit using the same
Hwang et al. Detection of cells producing murine interferon‐α using antipeptide antibodies
YAGI et al. An epitope chimeric antigen for the hepatitis C virus serological screening test
EP0672066A1 (en) Peptides from the c33 region of hcv, antibodies thereto and methods for the detection of hcv
WO1997024594A3 (en) Method of preparing and activating samples for radioimmunoassay and other test

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1992907699

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1992907699

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992907699

Country of ref document: EP